<span item_type="fundamental" item_id="0e36c144eb855c269ae8c2266104ee5c" counter_id="ST/US/KTTAW" env="prod"></span><span item_type="announcement" item_id="549437484218390529" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.66.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Therapeutics Segment</strong>: The company is focused on developing PAS-004, a next-generation macrocyclic mitogen-activated protein kinase (MEK) inhibitor, with ongoing clinical trials in the United States, Eastern Europe, Australia, South Korea, and the United States.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended June 30, 2025, the net loss was $3,716,157, compared to $3,866,249 for the same period in 2024, representing a decrease of 3.9%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li><li><strong>Loss from Operations</strong>: For the six months ended June 30, 2025, the loss from operations was $7,491,078, compared to $7,985,808 for the same period in 2024, representing a decrease of 6.2%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the six months ended June 30, 2025, net cash used in operating activities was $6,924,643, compared to $8,359,951 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: For the six months ended June 30, 2025, net cash provided by financing activities was $7,213,335.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Clinical Trials</strong>: The company is conducting a Phase 1/1b trial of PAS-004 in adult patients with neurofibromatosis type 1 (NF1) and expects to complete the FIH Phase 1 Dose Escalation Study in 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to seek FDA marketing approval for PAS-004 for the treatment of symptomatic plexiform neurofibromas (PNs) in both adult and pediatric patients with NF1. The company aims to conduct a Phase 1 trial for pediatric NF1-PN patients and complete registrational clinical trials in both adult and pediatric NF1-PN populations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li><li><strong>Non-Core Business</strong>: The company has two programs in the discovery stage, targeting amyotrophic lateral sclerosis (ALS) for PAS-003 and schizophrenia for PAS-001.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li><li><strong>Priority</strong>: The company expects research and development expenses to increase throughout fiscal year 2025 due to ongoing clinical trials and manufacturing costs related to PAS-004.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1841330/000121390025076557/ea0250837-10q_pasithea.htm"></span></li></ul>

PASITHEA THERAPEUTICS CORP C/WTS 12/08/2026 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.66